

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### STA bimekizumab for treating axial spondyloarthritis

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Final appraisal determination

(when no ACD was issued)

- |                                                                                                                               |
|-------------------------------------------------------------------------------------------------------------------------------|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|-------------------------------------------------------------------------------------------------------------------------------|

Yes. The company highlighted that the condition affects women more frequently and that women also typically experience disease which responds less well to some treatments. Issues about differences in the prevalence or incidence of a condition cannot be addressed in a technology evaluation so there is no action needed on this point.
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

- |                                                                                                                                                                      |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Yes. Further comments were made regarding the prevalence of the disease. Issues about differences in the prevalence or incidence of a condition cannot be addressed in a technology evaluation so there is no action needed on this point.
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

- |                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|----------------------------------------------------------------------------------------------------------------------------------|

No.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Recommendation 1.3 has been added to 'Take into account any communication difficulties, or physical, psychological, sensory or learning disabilities that could affect responses to the BASDAI and spinal pain VAS questionnaires, and make any appropriate adjustments'. This is in line with previous NICE technology appraisal guidance in this disease area.

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

N/A

**Approved by Associate Director (name):** .....Richard Diaz .....

**Date:** 25 August 2023